Coronary angioplasty reduces the risk of spontaneous myocardial infarction in chronic stable patients.

Original title: Percutaneous Coronary Intervention Versus Optimal Medical Therapy for Prevention of Spontaneous Myocardial Infarction in Subjects With Stable Ischemic Heart Disease. Reference: Sripal Bangalore et al. Circulation. 2013;127:769-781

In the context of coronary angioplasty complications may arise, such as a periprocedural infarction. However, this event does not have the same clinical consequences compared to a spontaneous infarction. 

The goal of this meta analysis was to evaluate the incidence of the different types of myocardial infarction in patients with stable ischemic heart disease treated with PCI vs. optimal medical therapy (OMT). 8070 patients with stable chronic angina were included from 12 randomized studies that compared PCI vs. OMT. The average follow up was 5 years (between 1.5 to 10.2 years) and only a small number of patients in the angioplasty group received drug eluting stents.

PCI was associated to a significant 24% incidence reduction of spontaneous acute myocardial infarction (RR=0.76; 95% IC, 0.58–0.99) (type 1 infarction of the universal definition). ON the other hand, PCI was associated with a greater incidence of periprocedural infarction (type 4 infarction). If we take into account all infarction events together, we won´t see any differences between both strategies. (RR=0.96; 95% CI, 0.74–1.21). PCI was also associated with a reduction in all cause mortality rate, though it did not reach a significant statistical value. (RR=0.88; 95% CI, 0.75–1.03).

Conclusion: 

PCI, compared to OMT, in patients with stable ischemic heart disease, was associated with a significant reduction of spontaneous MI risk (type 1 of the universal definition) and a tendency to lower mortality rate, although it did not reach a significant statistical value.

Editorial comment: 

A lot has been written about the important difference in prognosis of spontaneous MI vs. periprocedural MI. The whole work revolves around this detail, since the tally simply tracks the number of infarction events, but the risk these events involve is very different. This difference in terms of risk can be perceived in the tendency to a lower mortality in patients treated with PCI.

SOLACI.ORG

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

T-TEER: Beyond Traditional Pulmonary Hypertension Thresholds

Significant tricuspid regurgitation (TR) is associated with progressive functional deterioration, heart failure (HF) hospitalizations, and increased mortality. In recent years, transcatheter tricuspid edge-to-edge repair...

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

Left Atrial Appendage Closure in Spain: Sustained Growth and Favorable Real-World Outcomes

Oral anticoagulation remains the standard treatment for stroke prevention in patients with atrial fibrillation. However, many patients have a high bleeding risk or contraindications...